Proceedings of the Annual Meeting of the Society of Hematologic Oncology, 2014
Minimal Residual Disease in AML: Why Has It Lagged Behind Pediatric ALL?
Effect of Initial Body Mass Index on Survival Outcome of Patients With Acute Leukemia: A Single-Center Retrospective Study
Second Myeloid Malignancies in a Large Cohort of Patients With Chronic Lymphocytic Leukemia: A Single Institution Experience
How We Treat Myeloproliferative Neoplasms
New Therapeutic Approaches in Polycythemia Vera
Janus Kinase Inhibitors and Stem Cell Transplantation in Myelofibrosis
Which Patients Should Undergo Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes, and When Should We Do It?
Transformation of the Clinical Management of CMML Patients Through In-Depth Molecular Characterization
Treatment of Higher-Risk Myelodysplastic Syndromes After Failure of Hypomethylating Agents
Validation of the Lower-Risk MD Anderson Prognostic Scoring System for Patients With Myelodysplastic Syndrome
Practical Management of Lenalidomide-Related Rash
Allogeneic Transplantation for Unfavorable-Risk Acute Myeloid Leukemia
Decitabine and Sorafenib Therapy in FLT-3 ITD-Mutant Acute Myeloid Leukemia
Assessment of Molecular Markers in AML Patients: A Hospital-Based Study in Lebanon
Acute Myeloid Leukemia With t(v;5q33) Is Associated With Poor Overall Survival and Often Lacks Myelodysplastic Features
Novel Therapeutics for Therapy-Related Acute Myeloid Leukemia: 2014
Disseminated Intra-Abdominal Aspergilloma With Abdominal Wall Invasion in a Patient With Acute Myeloid Leukemia: A Case Report
Distinguishing the Causes of Pulmonary Infiltrates in Patients With Acute Leukemia
Relapsed Acute Myeloid Leukemia: Need for Innovative Treatment Strategies to Improve Outcome
Prognosis and Molecular Monitoring in Chronic Myeloid Leukemia
Factors Affecting Early Molecular Response in Chronic Myeloid Leukemia
Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia
Retrospective Study of Allogeneic Hematopoietic Stem Cell Transplantation in Philadelphia Chromosome–Positive Leukemia: 25 Years' Experience at Gustave Roussy Cancer Campus
Transformative Clinical Trials in Non-Hodgkin and Hodgkin Lymphomas
Hemophagocytic Lymphohistiocytosis in Malignant Hematology: Uncommon but Should Not Be Forgotten?
Imbalance of Pro- and Anti-Inflammatory Cytokines in Patients With cHL Persists Despite Treatment Compared With Control Subjects
Ocular Adnexal Lymphomas: Single-Center Experience
Investigating the Role of JAK/STAT Pathway on Dasatinib-Induced Apoptosis for CML Cell Model K562
Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1
Frequency of the ETV6-RUNX1, BCR-ABL1, TCF3-PBX1 and MLL-AFF1 fusion genes in Guatemalan Pediatric Acute Lymphoblastic Leukemia Patients and Its Ethnic Associations
Inotuzumab Ozogamicin (IO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) as Frontline Therapy for Older Patients (pts) and as Salvage Therapy for Adult with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)
Impact of initial body mass index (BMI) on survival outcome of patients with acute leukemia (AL): myth or reality?
Detection of Minimal Residual Disease Using Next Generation Sequencing for Antigen Receptor Gene Rearrangements in Acute Lymphoblastic Leukemia
Prognostic Factors in Patients with Refractory and Relapsed Acute Lymphocytic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (IO), a CD22 Monoclonal Antibody
Prognostic Significance of Copy Number Alterations in B-lineage Adult Acute Lymphoblastic Leukemia Patients Enrolled in Risk-adapted Protocols from the PETHEMA Group
Copy Number Alterations in patients with mature B (Burkitt-type) acute lymphoblastic leukaemia treated with specific immunochemotherapy
The prognostic significance of additional cytogenetic abnormalities in adults with Philadelphia chromosome positive acute lymphoblastic leukemia undergoing allogeneic stem cell transplant
Outcomes of second allogeneic hematopoietic stem cell Transplantation (Allo-SCT) in patients with acute lymphoblastic leukemia (ALL)
Characterization of new cryptic rearrangements of the erythropoietin receptor in Ph-like acute lymphoblastic leukemia
Retrospective outcomes in patients with BCR-ABL positive Acute Lymphoid Leukemia without Allogeneic stem cell transplantation at the Houston Methodist
Delays in Intensification are Common in Adults with Acute Lymphoblastic Leukemia (ALL), are Associated with Decreased Survival in Allogeneic Hematopoietic Cell Transplant (HCT) Patients
Germline exome variation in children with acute lymphoblastic leukemia (ALL): Preliminary Findings
Cytochrome P450 and drug metabolism in the stem cell niche
Therapeutic activity of a bi-specific T cell engaging, TCR-mimic monoclonal antibody to WT1 against human leukemias and cancers in mouse models
BL-8040, a CXCR4 antagonist, synergizes with the FLT3 inhibitor AC220 inducing apoptosis and reducing minimal residual disease to prolong survival of AML diseased mice
Does transfusion of aged red blood cells lead to adverse outcomes in Acute Myeloid Leukemia patients undergoing Hematopoietic stem cell Transplantation?
Incidence of and risk factors for acute myeloid leukemia involvement of the central nervous system
Tumor Suppressor Role for B55 alpha PP2A Isoform in AML
Impact of Therapy-Related De Novo Acute Myeloid Leukemia on Response and Survival
Allogeneic Stem Cell Transplantation In Patients With Acute Myeloid Leukemia: a report from the Austrian Stem Cell Transplantation Registry (ASCTR)
CYC065, potential therapeutic agent for AML and MLL leukaemia
Very High Dose Cytarabine as Salvage Therapy for Relapsed or Refractory Acute Myeloid Leukemia in the Setting of Intensified Anthracycline Induction and Post Stem-Cell Transplantation
Incidence Rate of Venous Thromboembolism (VTE) and Utilization of a VTE Prophylaxis Orderset Module In Hospitalized Patients With Leukemia
Heterogeneous effects of targeting WNT signaling in AML blasts
Mesenchymal Stem Cells Differentiate into Osteoblasts in the Presence of AML Cells through Up-regulation of RUNX2 and Induce Chemo-resistance
U2AF1 mutation in de novo myelodysplastic syndromes (MDS) and its genetic evolution profile of secondary acute myeloid leukemia (sAML): a comparative analysis of 68 paired matched samples
Characteristics of therapy-related myeloid neoplasms in breast cancer patients
Decitabine and sorafenib therapy in FLT3-ITD mutant acute myeloid leukemia- A case series
Acute Myeloid Leukemia with t(v;5q33-34) Does Not Always have Myelodysplastic Features but is Associated with Poor Outcome
DNMT3A mutations exert a dominant adverse effect in De novo acute myeloid leukemia with concurrent FLT3 and NPM1 mutations
Allogenic Stem Cell Transplant in Patients with Germline GATA2 Mutation
G-CSF Reduces ex vivo Acute Myeloid Leukemia Blasts Cells Viability in the Presence of Bone Marrow Stroma Cells
Reduced Intensity Conditioned (RIC), HLA-haploidentical BMT in AML
Decitabine enhances the expression of TAP1 facilitating antigen-specific immune responses in acute myeloid leukemia
What qualifies as “true” salvage therapy in acute myeloid leukemia?: CR rates with second salvage depending on type of first salvage
Decitabine Improves Outcomes in Older Patients with AML and Higher Blast Counts
Phase I/IIa trial of volasertib combined with decitabine in patients with acute myeloid leukemia (AML) ineligible for intensive therapy
Integrated Genomic Profiling, Therapy Response And Survival in Adult Acute Myelogenous Leukemia
Clinical description of acute promyelocytic leukemia (APL) patients receiving all-trans retinoic acid (ATRA) who develop pseudotumor cerebri: Incidence, diagnosis, outcomes, and recommendations for management
Phase III randomized trial of volasertib combined with low-dose cytarabine (LDAC) versus placebo plus LDAC in patients aged ≥65 years with previously untreated, acute myeloid leukemia (AML) ineligible for intensive remission induction therapy
ASXL1 Mutations in AML: Molecular Biomarker for Secondary AML?
A Novel Prognostic Model for Risk Stratification in Younger Patients with Intermediate Risk Acute Myeloid Leukemia (AML)
Next generation sequencing-based monitoring for minimal residual disease in acute myeloid leukemia
Pretreatment FMS like Tyrosine kinase-3 Internal Tandem duplication (FLT3-ITD) Mutant Allele Burden Does Not Predict Response to the Combination of Sorafenib and Azacytidine in Patients with Relapsed or High Risk Elderly Untreated Acute Myeloid Leukemia
Assessment of molecular markers in AML patients: A hospital-based study in Lebanon
Donor Derived Myelodysplastic Syndrome in a Pediatric Allogeneic Transplant Recipient
Relationship between blood cultures and antibiotic changes in neutropenic fever
Outcome of FLT3 ITD Mutated AML Patients Based on Different Treatment Strategies
High Pseudotumor Cerebri Incidence in Tretinoin and Arsenic Treated Acute Promyelocytic Leukemia and the Role of Topiramate After Acetazolamide Failure
Evaluating Packed Red Blood Cell (RBC) Product Utilization on Hematologic Malignancy Service (HMS): A Quality Improvement Initiative
A Case Report on Primary Gastro-Intestinal Aspergilloma with Abdominal Wall Invasion
Allogeneic Stem Cell Transplant in AML with Adverse Cytogenetics
Bleeding Diathesis Associated with Acquired von Willebrand Syndrome in Three Patients with Chronic Lymphocytic Leukemia
Second Interim Analysis of a Phase 3 Study Evaluating Idelalisib and Rituximab for Relapsed Chronic Lymphocytic Leukemia
Mutations in the Toll-like receptor/MYD88 pathway in young (≤50 years) CLL patients
Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Results From the Randomized Phase III RESONATE™ (PCYC-1112) Trial
Real-world treatment patterns in first line and relapsed Chronic Lymphocytic Leukemia (CLL)
Impact of the immunoglobulin heavy chain variable region mutational status in patients with low risk chronic lymphocytic leukemia
The Impact of NOTCH1 in the Prognosis of Chronic Lymphocytic Leukemia (CLL)
Long-Term Efficacy and Safety of Single-Agent Ibrutinib at 3 Years Follow-up in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL)
Activity and Tolerability of Ibrutinib in Combination With Ofatumumab in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Second Myeloid and Lymphoid Malignancies in patients with Chronic Lymphocytic Leukemia
Cardiovascular Adverse Events Associated with Ibrutinib in Chronic Lymphocytic Leukemia Patients
Normalization of B2-microglobulin During the First Year of Treatment is Predictive for Prolonged Progression-free and Overall Survival in CLL Treated with FCR or Ibrutinib-based Regimens
Investigating The Role of JAK/STAT Pathway upon Dasatinib Induced Apoptosis for CML Cell Model K562
A retrospective study of the allogeneic hematopoietic stem cell transplantation in Ph+ leukemia patients: the 25 years’ experience of Gustave Roussy Cancer Center
EPIC: A Phase 3 Trial of Ponatinib Compared With Imatinib in CP-CML Patients
High-Resolution Analysis of the Relationship Between Ponatinib Dose and Molecular Response in CP-CML Patients in the PACE Trial
Development of a sensitive, quantitative multiplex BCR-ABL1 assay aligned directly to the who primary standard reference materials to report expression on the International Scale
miR17 Suppresses Cell Proliferation in Zoledronic Acid Treated Chronic Myeloid Leukemia Cells by Inducing Autophagy
Detection of JAK2 V617F mutation, secondary to the presence of BCR-ABL1 translocation in a patient with chronic myeloid leukemia: report of a case and review of the literature
Standard and High Sensitivity Molecular Analysis in Chronic Myeloid Leukemia Patients Candidate to Discontinuation of Tyrosine Kinase Inhibitors
Molecular response assessment at 3 months time point is better in late chronic phase chronic myeloid leukemia patients
Resveratrol Increases CHD4 Gene Expression and Regulates Wnt Signaling in Chronic Myeloid Leukemia
Targeting p53 in CML Chronic Phase Leukemia Stem Cells
Prognostic Significance of Survivin Expression in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP Therapy: A Report from the International DLBCL Rituximab-CHOP Consortium Program
Epstein-Barr Virus-Positive Plasmacytoma in Immunocompetent Patients
Development of a novel humanized anti-CD20 chimeric antigen receptor; Effect on the CD20 down-regulated and mAb therapy resistant tumor cells
Ocular Adnexal Lymphomas: Experience of Single Center
Diffuse Large B-Cell Lymphoma in adults aged 65 years and older: A retrospective multicenter analysis of clinical characteristics and therapeutic outcomes
Cost of treatment failure in patients with mantle cell lymphoma: results of a large U.S. observational study
Hairy cell leukemia cell lines lack signature BRAF mutations of typical disease and MAP2K1 mutations of atypical disease
Retrospective Comparison of the Effectiveness of Various Treatment Modalities of Extragastric MALT Lymphoma: A single center analysis
EZH2-Activating Mutations in DLBCL Are Easily Predictable by Routine Immunohistochemistry Analysis: a Tool to More Efficiently Define EZH2 Inhibitor-Sensitive Patients?
Akt activation confers an inferior survival in patients with activated B-cell subtype of diffuse large B-cell lymphoma: a report from The International DLBCL Rituximab-CHOP Consortium Program
Large scale phophoproteomic analysis reveals that Wiskott-Aldrich syndrome protein regulates the oncogenic potential of anaplastic large cell lymphoma
Brentuximab Vedotin in refractory or relapsed Peripheral T-cell Lymphoma: The French name patient program experience in 66 patients
Impact of treatment on IL-4, IL-6, IL-10 and sCD25 levels in patients with Hodgkin’s Lymphoma
MYC Signatures and Characterization of MYC-Driven Aggressive B-Cell Lymphoma
Nuclear coexpression of NF-κB subunit c-Rel and p53 mutants confers significantly poor survival in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: A Report from the International DLBCL Rituximab-CHOP Consortium
The prognostic value of molecular bone marrow involvement in aggressive lymphoma patients
Reversible mobilization of lymphoma cells to the peripheral blood by Plerixafor
A Phase 2 Study of Lenalidomide, Rituximab, Cyclophosphamide and Dexamethasone (LR-CD) for Untreated Low Grade Non-Hodgkin Lymphoma Requiring Therapy
Mantle Cell Lymphoma (MCL) Treatment Patterns, Healthcare Resource Use (HRU), and Costs in the United States
Elucidation of B cell receptor signaling in Burkitt’s lymphoma reveals novel signaling nodes with potential therapeutic relevance
Hemophagocytic Lymphohistiocytosis (HLH) in Malignant Hematology: Uncommon but Should Not be Forgotten?
Long-Term Complete Responses to Combination Therapies and Allogenic Stem Cell Transplants in Sézary Patients
Clinical and Biological significance of MYC/BCL6 dual gene rearrangements and protein co-expression in de novo diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program
Extramedullary involvement at diagnosis is a poor prognostic factor in patients with Waldenstrom macroglobulinemia: The MD Anderson Cancer Center experience
Central Nervous System Involvement in T-cell Lymphoma: A Single Center Experience
Analysis of Prognostic Factors in Patients with HIV-Associated Aggressive B-Cell Non-Hodgkin Lymphomas
The role of pregnancy induced hormonal milieu in lymphoma progression
A third of transfusion-dependent patients with myelodysplastic syndromes (MDS) develop alloantibodies against red blood cell antigens
Underexpression of EZH2 in Myelodysplastic Syndromes
Chromosomal 3 Abnormalities in Myelodysplastic Syndromes: Implications on Prognosis and Response to Treatment
Validation of the Lower Risk MD Anderson Prognostic Scoring System for Patients with Myelodysplastic Syndromes (MDS)
Phase I study of volasertib combined with azacitidine in patients with previously untreated, high-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) ineligible for high-intensity therapy
Practical Guide to Management of Lenalidomide-Related Rash in Patients with MDS
ASXL1 and SETBP1 Mutations and Their Prognostic Contribution in Chronic Myelomonocytic Leukemia: An International Study of 466 Patients
Long-term bone marrow stromal changes in patients with myelofibrosis treated with ruxolitinib
Prognostic model based on JAK2, CALR and MPL mutation status and age predicts the survival outcome of patients with primary myelofibrosis
Mutational Profiling of JAK2V617F vs. CALR mutated Primary Myelofibrosis
Association of lymphoma/myeloma and Philadelphia-chromosome negative myeloproliferative neoplasms: clinical characteristics, therapy and outcome
To Treat or Not to Treat: A Novel Stratification of Myelofibrosis Patients by Likelihood of Response to JAK2 Inhibitors
Evaluation of JAK2 V617F mutation and BCR-ABL translocation status in the work-up of MPN: A hospital-based study in Lebanon
Successful treatment of hydroxyurea-associated chronic leg ulcers and squamous cell carcinoma in a patient with essential thrombocythemia
Palmitic acid as an anti-multiple myeloma molecule was sorted out from lipid profiling by secondary ion mass spectrometry
Utility of Serum Free Light Chain Measurements in Multiple Myeloma Patients Not Achieving Complete Response
Measurement of the proliferation of clonal plasma cells by multiparametric flow cytometry is a clinically useful tool in relapsed multiple myeloma
The Reversal of Renal Impairment and its Impact on Survival in Newly Diagnosed Multiple Myeloma Patients
First Report of NRAS Mutations Contributing to Donor Cell Leukemia after allogeneic Bone Marrow Transplantation for Severe Aplastic Anemia
Drug induced depletion of myeloid progenitors in bone marrow samples as an ex vivo estimation of hematotoxicity
Continuing Medical Education Post-Test [Course Code: E112406],